Skip to content
Nonprofiteer
← LUPUS RESEARCH ALLIANCE INC

Form 990 for tax year 2023

Filed by LUPUS RESEARCH ALLIANCE INC.

Totals

Total revenue
$50,861,497
Total expenses
$35,405,251
Contributions and grants received
$41,038,661
Grants paid
$16,607,966
Program service revenue
$1,197,560
Investment income
$8,063,403
Other revenue
$561,873
Total assets, end of year
$111,947,130
Total liabilities, end of year
$36,633,486
Net assets or fund balances, end of year
$75,313,644
Program services expenses (Part IX)
$28,218,305
Management and general expenses
$3,468,449
Fundraising expenses
$3,718,497
Program service expenses (Part III)
$28,218,305

Program services were 79.7% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $4,303,717

  • 1e · Government grants (contributions)

    $334,880

  • 1f · All other contributions, gifts and grants

    $36,400,064

  • 1g · Noncash contributions included above

    $109,513

  • 2a · Program service revenue: LUCIN CONSULTING REVENUE

    total $1,197,560 · related or exempt $1,197,560

  • 3 · Investment income

    total $1,929,526 · excluded $1,929,526

  • 7a · Gross sales of assets other than inventory

    securities $11,008,109

  • 7b · Less cost or other basis and sales expenses

    securities $4,874,232

  • 7c · Gain or loss

    securities $6,133,877

  • 7d · Net gain or loss

    total $6,133,877 · excluded $6,133,877

  • 8a · Fundraising events: gross income

    $504,285

  • 8a · Fundraising events: contributions included on line 1c

    $4,303,717

  • 8b · Fundraising events: direct expenses

    $504,285

  • 8c · Net income from fundraising events

    total $0

  • 11a · Other revenue: SUBLET INCOME

    total $561,873 · excluded $561,873

  • 11e · Other revenue, total

    $561,873

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $14,585,339 · program services $14,585,339

  • 2 · Grants to domestic individuals

    total $123,168 · program services $123,168

  • 3 · Grants to foreign organizations and individuals

    total $1,899,459 · program services $1,899,459

  • 5 · Compensation of officers, directors and key employees

    total $2,313,770 · program services $1,322,488 · management and general $492,698 · fundraising $498,584

  • 7 · Other salaries and wages

    total $4,795,752 · program services $2,909,628 · management and general $943,331 · fundraising $942,793

  • 8 · Pension plan contributions

    total $312,283 · program services $192,072 · management and general $57,477 · fundraising $62,734

  • 9 · Other employee benefits

    total $1,140,569 · program services $685,495 · management and general $228,652 · fundraising $226,422

  • 10 · Payroll taxes

    total $494,966 · program services $295,376 · management and general $99,553 · fundraising $100,037

  • 11b · Fees: legal

    total $200,125 · program services $112,170 · management and general $36,747 · fundraising $51,208

  • 11c · Fees: accounting

    total $66,669 · management and general $66,669

  • 11d · Fees: lobbying

    total $122,617 · program services $122,617

  • 11e · Fees: professional fundraising services

    total $72,500 · fundraising $72,500

  • 11f · Fees: investment management

    total $253,159 · management and general $253,159

  • 11g · Fees: other

    total $2,856,588 · program services $1,587,861 · management and general $560,351 · fundraising $708,376

  • 13 · Office expenses

    total $161,707 · program services $86,477 · management and general $51,702 · fundraising $23,528

  • 14 · Information technology

    total $2,021,296 · program services $1,719,031 · management and general $178,274 · fundraising $123,991

  • 16 · Occupancy

    total $864,336 · program services $515,800 · management and general $173,845 · fundraising $174,691

  • 17 · Travel

    total $577,630 · program services $378,293 · management and general $141,483 · fundraising $57,854

  • 19 · Conferences, conventions and meetings

    total $1,247,157 · program services $1,152,729 · management and general $65,370 · fundraising $29,058

  • 22 · Depreciation, depletion and amortization

    total $107,185 · program services $64,105 · management and general $21,613 · fundraising $21,467

  • 23 · Insurance

    total $76,177 · program services $49,444 · management and general $13,334 · fundraising $13,399

  • 24a · Other expenses: PRINTING & PUBLICATIONS

    total $356,286 · program services $50,184 · management and general $30,018 · fundraising $276,084

  • 24b · Other expenses: CLINICAL STUDIES

    total $283,506 · program services $283,506

  • 24c · Other expenses: POSTAGE, SHIPPING & DEL

    total $160,149 · program services $4,339 · management and general $25,963 · fundraising $129,847

  • 24d · Other expenses: DATA PROCESSING

    total $134,072 · program services $33,633 · management and general $10,626 · fundraising $89,813

  • 24e · All other expenses

    total $178,786 · program services $45,091 · management and general $17,584 · fundraising $116,111

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $5,098,361 · end of year $4,319,024

  • 2 · Savings and temporary cash investments

    beginning of year $864,824 · end of year $255,096

  • 3 · Pledges and grants receivable

    beginning of year $1,416,005 · end of year $21,589,284

  • 4 · Accounts receivable

    beginning of year $626,727 · end of year $336,389

  • 9 · Prepaid expenses and deferred charges

    beginning of year $567,776 · end of year $826,852

  • 10a · Land, buildings and equipment: cost or other basis

    $1,039,848

  • 10b · Land, buildings and equipment: accumulated depreciation

    $777,103

  • 10c · Land, buildings and equipment, net

    beginning of year $229,852 · end of year $262,745

  • 11 · Investments: publicly traded securities

    beginning of year $85,820,065 · end of year $80,913,435

  • 12 · Investments: other securities

    beginning of year $1,033,847 · end of year $855,454

  • 15 · Other assets

    beginning of year $3,249,835 · end of year $2,588,851

  • 17 · Accounts payable and accrued expenses

    beginning of year $878,056 · end of year $1,362,369

  • 18 · Grants payable

    beginning of year $29,652,068 · end of year $31,537,305

  • 25 · Other liabilities

    beginning of year $4,845,583 · end of year $3,733,812

  • 27 · Net assets without donor restrictions

    beginning of year $61,152,445 · end of year $47,936,256

  • 28 · Net assets with donor restrictions

    beginning of year $2,379,140 · end of year $27,377,388

Mission and programs · 2023

Mission

PUTTING PEOPLE WITH LUPUS AT THE CENTER OF ALL WE DO, THE LUPUS RESEARCH ALLIANCE DRIVES THE DISCOVERY & DEVELOPMENT OF NEXT GENERATION LUPUS DIAGNOSTICS AND CURATIVE TREATMENTS THROUGH INNOVATIVE RESEARCH & COLLABORATIONS.

Activities or mission (Part I)

FREEING THE WORLD OF LUPUS.

  • Withheld by Nonprofiteer: this text may name a private individual.

    Expenses $14,963,989 · Grants $13,851,951

  • SCIENTIFIC PROGRAMS:IN 2023, THE LUPUS RESEARCH ALLIANCE (LRA) MAINTAINED THE MOMENTUM OF ITS SCIENTIFIC PROGRAMS. THE LRA'S PROGRAMS' GROWTH WAS DRIVEN BY BUILDING ON ESTABLISHED PROGRAMS WHILE CREATING OPPORTUNITIES FOR COLLABORATION WITH DIFFERENT SECTORS. NOTABLE ACHIEVEMENTS FROM 2023 INCLUDE THE FOLLOWING: COLLABORATED WITH LRA RESEARCH COMMITTEE OF THE BOARD AND SCIENTIFIC ADVISORY BOARD TO BOTH IMPLEMENT EFFICIENTLY OUR EXISTING RESEARCH STRATEGY AND TO DEVELOP AN UPDATED PLAN FOR THE NEXT FIVE YEARS. DEVELOPED AN AMBITIOUS RESEARCH STRATEGIC PLAN FOR THE LRA FOR THE NEXT FIVE YEARS (2024-2028). COMPLETED THE MOST COMPREHENSIVE RESEARCH PORTFOLIO EVALUATION FOR THE LRA TO DATE GENERATING SUBSTANTIAL DATA ON THE OUTCOMES OF LRA'S RESEARCH INVESTMENTS THAT IS BEING USED TO REFINE LRA'S RESEARCH PORTFOLIO AND TO RAISE ADDITIONAL FUNDS BY DEVELOPMENT. EXPANDED LRA'S RESEARCH PORTFOLIO WITH 26 NEW, INNOVATIVE, AND POTENTIALLY IMPACTFUL RESEARCH PROJECTS. LAUNCHED CRITICAL EFFORTS TO FURTHER MAXIMIZE LRA'S RESEARCH INVESTMENTS INCLUDING A COLLABORATIVE PROGRAM ACROSS THE GTSA GRANTEES AND A DLR TRAINING PROGRAM. FURTHER OPTIMIZED THE LUPUS INSIGHT PRIZE PROGRAM TO STIMULATE THE SUBMISSION OF A ROBUST POOL OF COMPELLING NOMINATIONS. ESTABLISHED THE LUPUS ACCELERATING BREAKTHROUGHS CONSORTIUM (LUPUS ABC)-- THE FIRST PUBLIC PRIVATE PARTNERSHIP WITH THE FDA DEDICATED TO ACCELERATING THE DEVELOPMENT OF SAFER AND MORE EFFECTIVE THERAPEUTICS FOR LUPUS. SINCE ITS CREATION, LUPUS ABC HAS LAUNCHED FOUR PROJECTS WITH THE PARTICIPATION OF KEY STAKEHOLDERS--INCLUDING REPRESENTATIVES FROM ACADEMIA, INDUSTRY, PROFESSIONAL SOCIETIES, GOVERNMENTAL AGENCIES, PATIENT ADVOCACY GROUPS, AND INDIVIDUALS WITH LUPUS. CONTINUED TO ESTABLISH KEY INFRASTRUCTURE COMPONENTS OF THE LUPUS NEXUS, THE LRA'S REGISTRY, BIOREPOSITORY AND RESEARCH INFORMATION EXCHANGE PLATFORM. THE LUPUS NEXUS WILL BE A SOURCE OF HIGHLY CURATED DATA AND BIOSPECIMENS TO CATALYZE GLOBAL COLLABORATION, RESEARCH INNOVATION, AND PRECISION MEDICINE APPROACHES TO ACCELERATE LUPUS RESEARCH AND DRUG DEVELOPMENT. MAINTAINED A STRONG ENGAGEMENT WITH INDUSTRY THROUGH THE LUPUS INDUSTRY COUNCIL (LIC). LIC MEMBERS ARE INVOLVED IN VARIOUS LRA INITIATIVES INCLUDING THE LUPUS ABC, LUPUS NEXUS, AND LIC WORKING GROUPS. DURING 2023, THE (LRA) CONVENED AN ANNUAL SCIENTIFIC CONFERENCE, THE FORUM FOR DISCOVERY, TO PROVIDE AN OPPORTUNITY FOR LRA-FUNDED SCIENTISTS TO SHARE THEIR RESEARCH DISCOVERIES MADE POSSIBLE BY LRA'S SUPPORT ADDITIONAL GOALS OF THE MEETING INCLUDE PROMOTING COLLABORATIONS, STIMULATING NEW IDEAS AND PROJECTS, AND ENABLING INTERACTIONS BETWEEN INVESTIGATORS FROM ACADEMIA AND INDUSTRY. CONTINUED TO NURTURE COLLABORATION BY HOSTING INTERNAL AND EXTERNAL MEETINGS. THIS INCLUDED RESEARCH COMMITTEE MEETINGS WHERE MEMBERS OF OUR BOARD OF DIRECTORS AS WELL AS TOP-LEVEL RESEARCHERS DISCUSSED OUR PORTFOLIO AND UPCOMING STRATEGIC STEPS; SCIENTIFIC ADVISORY BOARD MEETINGS WHERE HIGHLY REGARDED SCIENTIFIC ADVISORS REVIEW GRANT APPLICATION SUBMISSIONS AND DISCUSS FUTURE AND OVERALL RESEARCH STRATEGY FOR THE ORGANIZATION; 2023 FORUM FOR DISCOVERY (ANNUAL INVESTIGATOR'S MEETING); GRANT-SPECIFIC STUDY SECTIONS WHERE INVITED RESEARCHERS DISCUSSED AND REVIEWED APPLICATIONS SUBMITTED TO THE LRA. LUPUS THERAPEUTICS, LLC:THE LRA FOUNDED LUPUS THERAPEUTICS, LLC (LT) AS THE CLINICAL RESEARCH AFFILIATE OF THE LRA IN 2018 . WITH THIS ADDITION, THE LRA IS THE ONLY ORGANIZATION LEADING LUPUS RESEARCH ACROSS THE CONTINUUM FROM ACCELERATING BASIC DISCOVERIES IN THE LAB THROUGH CLINICAL EVALUATION OF NEW THERAPIES. MANY OF THE BASIC RESEARCH BREAKTHROUGHS SUPPORTED BY THE LRA HAVE HELPED UNRAVEL THE COMPLEXITIES OF LUPUS AND ENABLED THE DEVELOPMENT OF POTENTIAL TREATMENTS AND DIAGNOSTICS NOW IN CLINICAL STUDIES. LT IS ACTIVELY SUPPORTING SEVERAL CLINICAL STUDIES FOR NEW THERAPIES THROUGH THE LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN). LT OVERSEES LUCIN, A NORTH AMERICA-BASED LUPUS CLINICAL TRIALS NETWORK OF 50+ PREMIER RESEARCH MEDICAL CENTERS. THE LRA PROVIDED OVER $2.6 MILLION IN 1-YEAR GRANTS IN 2023 TO CONTINUE FUNDING TOP ACADEMIC CENTERS TO FOSTER ROBUST, HIGH QUALITY CLINICAL TRIAL CONDUCT WITH PARTICIPATION ACROSS NORTH AMERICA.LT ALSO OFFERS EXPERTISE COMBINED WITH THAT OF 200+ LUCIN PROVIDERS AND THE LRA THROUGH COMMUNITY-BASED AND INTERNAL PROGRAMS TO ENSURE EQUITABLE ACCESS, PARTICIPATION AND REPRESENTATION OF THE DIVERSE LUPUS COMMUNITY.

    Expenses $12,470,434 · Grants $2,632,847 · Revenue $1,197,560

  • PUBLIC POLICY:THE LUPUS RESEARCH ALLIANCE'S ADVOCACY EFFORTS FOCUS ON URGING CONGRESS TO PROVIDE THE FUNDS NEEDED TO SUPPORT RESEARCH INTO LUPUS THAT CAN LEAD TO BETTER TREATMENTS AND, ULTIMATELY, A CURE. EFFORTS ALSO INCLUDE WAYS TO ENSURE INCREASED DIVERSITY IN CLINICAL TRIALS AND REDUCING BARRIERS TO ENROLLMENT FOR ALL WHO WANT TO PARTICIPATE. THE TOP GOALS OF THE LUPUS RESEARCH ALLIANCE PUBLIC POLICY PROGRAM FOCUS MAINLY ON FUNDING FOR LUPUS RESEARCH THAT WILL LEAD TO BETTER TREATMENTS AND ELIMINATE RACIAL DISPARITIES IN HEALTHCARE. GOALS INCLUDE: INCREASING FEDERAL FUNDING FOR LUPUS RESEARCH BY RAISING OVERALL NATIONAL INSTITUTES OF HEALTH (NIH) FUNDS AND SECURE ADDITIONAL FUNDING FOR LUPUS RESEARCH THROUGH OTHER KEY FEDERAL AGENCIES INCLUDING THE DEPARTMENT OF DEFENSE (DOD); SUPPORTING THE LRA'S PARTNERSHIP WITH THE FDA, THE LUPUS ACCELERATING BREAKTHROUGHS CONSORTIUM (LUPUS ABC); AND ENSURING THE PATIENT VOICE IS INCORPORATED IN THE DRUG DEVELOPMENT PROCESS. VOLUNTEERS ACROSS THE COUNTRY HELP AMPLIFY THESE OUTREACH EFFORTS.THROUGH THE LUPUS RESEARCH ALLIANCE ONGOING PUBLIC POLICY PROGRAM EFFORTS, SIGNIFICANT FUNDING FOR LUPUS RESEARCH HAS BEEN OBTAINED UNDER THE DEPARTMENT OF DEFENSE (DOD) CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS (CDMRP) OPERATED BY THE ARMY MEDICAL RESEARCH AND MATERIEL COMMAND. GIVEN THE HIGH DEMAND FOR NEW RESEARCH ALONGSIDE THE RISING NUMBERS OF WOMEN TREATED AT MILITARY HEALTH FACILITIES AS WELL AS THE LINK BETWEEN POST-TRAUMATIC STRESS DISORDER (PTSD) AND THE DEVELOPMENT OF AN AUTOIMMUNEDISEASE, THE LUPUS RESEARCH ALLIANCE REQUESTS THAT CONGRESS INCREASE ITS INVESTMENT AND PROVIDE $15 MILLION FOR THE LUPUS RESEARCH PROGRAM IN THE CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS OPERATED UNDER THE DEFENSE HEALTH PROGRAM IN THE DEFENSE APPROPRIATIONS BILL. THIS ADDITIONAL INVESTMENT IS CRITICAL FOR DISCOVERIES THAT CAN MAKE A DIFFERENCE IN PATIENTS' ABILITY TO BE THE BEST VERSION OF THEMSELVES. THE LRA LED THE PUSH FOR THE CREATION OF THE LUPUS RESEARCH PROGRAM, WHICH WAS FIRST FUNDED WITH $5 MILLION IN 2017 AND INCREASED TO $10 MILLION PER YEAR IN 2020. LRA LEADERSHIP, OUR ADVOCATES, AND ALLIED MEMBERS OF CONGRESS ARE WORKING TO ADVANCE RESEARCH PRIORITIES LIKE THIS THAT ARE CRITICAL TO THE LUPUS RESEARCH ALLIANCE AND ALL PEOPLE IMPACTED BY LUPUS.IN 2023 THE LRA INTRODUCED THE LUPUS ACCELERATING BREAKTHROUGHS CONSORTIUM (LUPUS ABC) AS THE FIRST PUBLIC-PRIVATE PARTNERSHIP WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) THAT FOCUSES SPECIFICALLY ON ADVANCING THE DEVELOPMENT OF SAFER AND MORE EFFECTIVE TREATMENTS URGENTLY NEEDED FOR PEOPLE WITH LUPUS. IN COLLABORATION WITH KEY STAKEHOLDERS, LUPUS ABC IS BRINGING TOGETHER PEOPLE WITH LUPUS, FEDERAL AGENCIES, MEDICAL SOCIETIES, ADVOCACY GROUPS, INDUSTRY, ACADEMIC CLINICAL RESEARCHERS, AND SCIENTISTS, WITH THE FDA, TO OVERCOME THE SCIENTIFIC HURDLES IN DRUG DEVELOPMENT THAT ARE BEYOND THE CAPACITY OF ANY SINGLE ENTITY.THE LRA ALSO WORKED TO INCLUDE LANGUAGE THAT ACCOMPANIES THE AGRICULTURE, RURAL DEVELOPMENT, FOOD AND DRUG ADMINISTRATION (FDA) BILL TO SUPPORT ACCELERATING LUPUS THERAPIES. BOTH THE HOUSE AND SENATE APPROPRIATIONS COMMITTEES HAVE INCLUDED IMPORTANT LANGUAGE RELEVANT TO LUPUS SIMILAR TO WHAT LRA REQUESTED. THE FOLLOWING LANGUAGE WAS INCLUDED IN THE SENATE REPORT:THE COMMITTEE IS AWARE OF BARRIERS THAT HAVE LONG AFFECTED THE DEVELOPMENT OF THERAPEUTICS FOR LUPUS, A DISEASE THAT PRIMARILY TARGETS WOMEN. A CHRONIC AND COMPLEX AUTOIMMUNE DISEASE, LUPUS CAN AFFECT THE JOINTS, SKIN, BRAIN, LUNGS, KIDNEYS, AND BLOOD VESSELS, CAUSING WIDESPREAD INFLAMMATION AND TISSUE DAMAGE IN THE AFFECTED ORGAN. THE COMMITTEE IS PLEASED THAT FDA PARTICIPATED IN AN EXTERNALLY-LED PATIENT-FOCUSED DRUG DEVELOPMENT MEETING WITH THE LUPUS COMMUNITY AND IDENTIFIED SOME OF THESE BARRIERS AND THAT POTENTIAL TREATMENTS ARE NOW IN CLINICAL TRIALS. THE COMMITTEE URGES FDA TO EXPEDITE ITS ONGOING WORK WITH THE LUPUS COMMUNITY TO DEVELOP SOLUTIONS TO IDENTIFIED BARRIERS THAT WILL ACCELERATE DEVELOPMENT OF NEW THERAPIES.ONGOING ADVOCACY FOCUSES ON ENSURING LEGISLATION THAT SECURES THE FEDERAL FUNDING SUPPORT NECESSARY TO AFFORD INVESTIGATORS THE RESOURCES TO FOLLOW THROUGH WITH RESEARCH DISCOVERIES THAT WILL IMPROVE THE UNDERSTANDING OF AND TREATMENT FOR LUPUS. EACH SPRING, LUPUS RESEARCH ADVOCATES MEET WITH MEMBERS OF CONGRESS AND THEIR STAFF TO DESCRIBE THEIR PERSONAL LUPUS JOURNEY AND HOW THE DISEASE HAS AFFECTED THEIR LIFE, AND TO REQUEST SPECIFIC POLICIES THAT WILL MOVE LUPUS RESEARCH FORWARD. THE GOAL IS TO INCREASE AWARENESS OF LUPUS AND THE IMPACT IT HAS ON PEOPLE'S DAILY LIVES TO MEMBERS OF CONGRESS AND TO REQUEST THEIR SUPPORT FOR INCREASED FUNDING FOR LUPUS RESEARCH FROM FEDERAL PROGRAMS SUCH AS THE NIH AND CDMRP.

    Expenses $783,882 · Grants $123,168

As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here. A text marked withheld matched a screen for wording that may name a private individual, such as an honorific or "in memory of". Most of what it withholds names no one; it is withheld so that what does is never shown.

Listed in Part VII

  • IRA AKSELRAD

    CO-CHAIR

    Total calculated
    $0
    Hours/week
    1

  • RICHARD K DESCHERER

    CO-CHAIR

    Total calculated
    $0
    Hours/week
    1

  • JOSEPH MAURIELLO

    TREASURER

    Total calculated
    $0
    Hours/week
    1

  • ANNA FISCH

    SECRETARY

    Total calculated
    $0
    Hours/week
    1

  • JAMES ANDREW

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • BISHOP RUDY V CARLTON

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • WILLIE COLON

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • JENNIFER DAKIN

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • JENNIE DESCHERER

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • KATEY DRISCOLL

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • SIR MARC FELDMANN

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • MOTI FERDER

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • JOE GERMANOTTA

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • DAVID KIES

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • DANIEL LAVECCHIA

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • VERONICA VARGAS LUPO

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • MOLLY MCCABE

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • NADEEM MEGHJI

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • WILLIAM J MULVIHILL

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • NIDHI PATEL

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • ROBERT SEDER MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • DANIEL J WALLACE

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • JULIUS WILLIAMS

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • WILLIAM WOLFE

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • SPENCER ZWICK

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1

  • ALBERT ROY

    CEO AND PRESIDENT

    Total calculated
    $522,768
    From this org
    $435,807
    From related orgs
    $0
    Other
    $86,961
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $364,000
    Bonus
    $70,000
    Other
    $1,807
    Deferred
    $33,000
    Nontaxable benefits
    $53,961
    Filer's total
    $522,768

  • STACIE BELL PHD

    EXECUTIVE VP, LUPUS THERAPEUTICS

    Total calculated
    $313,258
    From this org
    $276,405
    From related orgs
    $0
    Other
    $36,853
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $244,792
    Bonus
    $30,000
    Other
    $1,613
    Deferred
    $10,733
    Nontaxable benefits
    $26,120
    Filer's total
    $313,258

  • DEBRA ROSE

    VP AND CHIEF FINANCE OFFIC

    Total calculated
    $304,796
    From this org
    $249,684
    From related orgs
    $0
    Other
    $55,112
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $227,115
    Bonus
    $20,000
    Other
    $2,569
    Deferred
    $29,582
    Nontaxable benefits
    $25,530
    Filer's total
    $304,796

  • TEODORA STAEVA

    VP AND CHIEF SCIENTIFIC OF

    Total calculated
    $408,297
    From this org
    $329,890
    From related orgs
    $0
    Other
    $78,407
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $277,824
    Bonus
    $50,000
    Other
    $2,066
    Deferred
    $32,782
    Nontaxable benefits
    $45,625
    Filer's total
    $408,297

  • ANDREA O'NEILL

    VP AND CHIEF DEVELOPMENT O

    Total calculated
    $319,414
    From this org
    $272,633
    From related orgs
    $0
    Other
    $46,781
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $235,700
    Bonus
    $35,000
    Other
    $1,933
    Deferred
    $29,777
    Nontaxable benefits
    $17,004
    Filer's total
    $319,414

  • PENELOPE MITCHELL

    VP OF COMMUNICATIONS

    Total calculated
    $234,865
    From this org
    $194,362
    From related orgs
    $0
    Other
    $40,503
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $181,600
    Bonus
    $10,000
    Other
    $2,762
    Deferred
    $14,736
    Nontaxable benefits
    $25,767
    Filer's total
    $234,865

  • LUKE EASLEY

    VP OF HR & ADMINISTRATION

    Total calculated
    $210,372
    From this org
    $183,964
    From related orgs
    $0
    Other
    $26,408
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $158,333
    Bonus
    $25,000
    Other
    $631
    Deferred
    $7,017
    Nontaxable benefits
    $19,391
    Filer's total
    $210,372

  • DEVON KELLY

    LUPUS NEXUS DIRECTOR

    Total calculated
    $268,100
    From this org
    $222,993
    From related orgs
    $0
    Other
    $45,107
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $208,000
    Bonus
    $12,480
    Other
    $2,513
    Deferred
    $19,162
    Nontaxable benefits
    $25,945
    Filer's total
    $268,100

  • DOREY NEILINGER

    SENIOR DIRECTOR OF PHILANT

    Total calculated
    $220,270
    From this org
    $179,452
    From related orgs
    $0
    Other
    $40,818
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $176,000
    Bonus
    $0
    Other
    $3,452
    Deferred
    $19,360
    Nontaxable benefits
    $21,458
    Filer's total
    $220,270

  • DIANE GROSS

    NATIONAL DIRECTOR OF ADVOC

    Total calculated
    $234,589
    From this org
    $194,794
    From related orgs
    $0
    Other
    $39,795
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $151,153
    Bonus
    $0
    Other
    $43,641
    Deferred
    $6,046
    Nontaxable benefits
    $33,749
    Filer's total
    $234,589

  • HOANG NGUYEN

    DIRECTOR OF SCIENTIFIC PARTNERSHIPS

    Total calculated
    $201,002
    From this org
    $163,397
    From related orgs
    $0
    Other
    $37,605
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $150,000
    Bonus
    $12,000
    Other
    $1,397
    Deferred
    $12,960
    Nontaxable benefits
    $24,645
    Filer's total
    $201,002

  • JONATHAN MARKS

    DIRECTOR OF CORPORATE DEVE

    Total calculated
    $204,651
    From this org
    $153,067
    From related orgs
    $0
    Other
    $51,584
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $152,100
    Bonus
    $0
    Other
    $967
    Deferred
    $16,731
    Nontaxable benefits
    $34,853
    Filer's total
    $204,651

  • KENNETH M FABER

    FORMER CEO & PRESIDENT

    Total calculated
    $400,000
    From this org
    $400,000
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $400,000
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $400,000

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Independent compensation consultant
  • 3 · Form 990 of other organizations
  • 3 · Written employment contract
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Disregarded entities

Part I: entities that legally are the filer and file no return of their own.

  • LUPUS THERAPEUTICS LLC

    LRA'S CLINICAL TRIAL AFFILIATE, OVERSEEING CLINICAL RESEARCH ACTIVITY · NY · income $2,333,551 · assets $884,491

    Directly controlled by YES

Provenance

Return type
form_990
Tax year
2023
Filed
17 September 2024
IRS schema version
2023v5.1
Source object
202412649349300226

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.